Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
PURPOSE: Prostate cancer (PCa) is a leading cause of cancer-related death. Upon androgen-deprivation therapy, the disease may progress further to castration-resistant PCa (CRPC) with a poor prognosis. MicroRNAs (miRNAs) are small non-coding RNAs, which play crucial roles in gene regulation. The aim of our study is to find CRPC-associated miRNAs and to evaluate their functional role. METHODS: In this study, 23 benign prostatic hyperplasia (BPH), 76 primary PCa, and 35 CRPC specimens were included. Total RNA extracted from tissue sections was used for miRNA profiling on the Affymetrix GSC 3000 platform. Subsequently, stem-loop RT-qPCR analysis was performed to validate the expression levels of selected miRNAs. PCa cell lines were transfected with miRNA mimics or inhibitors to evaluate the effects on cell proliferation, cell migration and cell invasion. RESULTS: In our profiling study, several miRNAs were found to be deregulated in CRPC compared to primary PCa tissue, of which miR-205 (- 4.5-fold; p = 0.0009), miR-92b (- 3.1 fold; p < 0.0001) were downregulated and miR-3195 (5.6-fold; p < 0.0001), miR-3687 (8.7-fold; p = 0.0006) and miR-4417 (5.0-fold; p = 0.0005) were most upregulated. While KLK3, miR-21 and miR-141 expression levels in androgen-treated VCaP and LNCaP cells were increased, the expression levels of miR-3687 and miR-4417 were reduced. None of the miRNAs were androgen-regulated in the AR-negative PC3 cell line. Overexpression of miR-3687 reduced cell migration and cell invasion, whilst miR-3195 enhanced cell migration. CONCLUSION: We have identified several novel deregulated miRNAs in CRPC tissue, including two microRNAs that are potentially involved in tumor invasion. Our data support the hypothesized involvement of miRNAs in PCa tumorigenesis and progression to CRPC. The applicability of these miRNAs as novel biomarkers for CRPC remains to be further investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, the expression of several microRNAs (miRs) identified as potential biomarkers for the early detection of CRPC (Arrighetti and Beretta, 2021; Rönnau et al., 2021), including miR-3687 and miR-205 were altered in the microfluidic devices containing LNCaPs.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Rönnau et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The ENCODE Project Consortium (2007) · Nature · doi:10.1038/nature05874 · Cited by 5,223 · cited 1×
“Non-coding RNAs (ncRNAs) play essential roles in key biological processes and can be involved in cancer pathogenesis [3, 4].”
BackgroundReal-time quantification of microRNAs by stem-loop RT-PCR
Chen, C. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni178 · Cited by 4,952 · cited 1×
“MiRNA expression was determined by stem-loop RT-qPCR analysis using 100 ng total RNA [13].”
MethodmiRBase: integrating microRNA annotation and deep-sequencing data
Kozomara, A., & Griffiths-Jones, S. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1027 · Cited by 3,634 · cited 1×
“MicroRNAs (miRNAs) are small ncRNAs that regulate gene expression at the posttranscriptional level by binding to the 3′UTR of target mRNAs leading to inhibition of mRNA translation and to mRNA degradation [4, 5].”
BackgroundCauses and consequences of microRNA dysregulation in cancer
Croce, C. M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2634 · Cited by 2,998 · cited 1×
“1 3 expressed in human cancer, and these miRNAs can act as oncomiRs or tumor suppressors [6, 7].”
BackgroundAR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710 · cited 1×
“It has been described that the AR and AR splice variants (ARV) are relevant in CRPC development and progression [23], and that wild-type AR and AR-Vs both activate different, yet overlapping, sets of target genes [24–26].”
BackgroundDi Leva, G., Garofalo, M., & Croce, C. M. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,672
Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.002 · Cited by 1,438
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785
Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study
Mestdagh, P., Hartmann, N., Baeriswyl, L., Andreasen, D., Bernard, N., Chen, C., Cheo, D., D'Andrade, P., DeMayo, M., Dennis, L., et al. (2014) · Nature Methods · doi:10.1038/nmeth.3014 · Cited by 660 · cited 1×
“Affymetrix microarray) showed lower sensitivity compared to other platforms, and that qPCR technology is superior with respect to sensitivity and accuracy [17].”
BackgroundAndrogen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer
Jalava, S. E., Urbanucci, A., Latonen, L., Waltering, K. K., Sahu, B., Jänne, O. A., Seppälä, J., Lähdesmäki, H., Tammela, T. L. J., & Visakorpi, T. (2012) · Oncogene · doi:10.1038/onc.2011.624 · Cited by 223 · cited 7×
“Seven androgen-regulated miRNAs, miR-21, miR-32, miR-99a, miR-99b, miR-148a, miR-221 and miR-590-5p, have been reported to be differentially expressed in CRPC compared to benign prostate hyperplasia (BPH) [10].”
BackgroundInfluentialBoll, K., Reiche, K., Kasack, K., Mörbt, N., Kretzschmar, A. K., Tomm, J. M., Verhaegh, G., Schalken, J., von Bergen, M., Horn, F., et al. (2013) · Oncogene · doi:10.1038/onc.2012.55 · Cited by 216 · cited 2×
“1a; Supplementary Table 4), confirming earlier reported findings [14].”
ResultSelf-citationAndrogen Receptor Splice Variants Dimerize to Transactivate Target Genes
Xu, D., Zhan, Y., Qi, Y., Cao, B., Bai, S., Xu, W., Gambhir, S. S., Lee, P., Sartor, O., Flemington, E. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0381 · Cited by 189
Xu, B., Wang, N., Wang, X., Tong, N., Shao, N., Tao, J., Li, P., Niu, X., Feng, N., Zhang, L., et al. (2012) · The Prostate · doi:10.1002/pros.22466 · Cited by 167 · cited 1×
“Overexpression of miR-146a, which is downregulated in CRPC tissue, inhibits cell growth, colony formation and cell migration [28].”
BackgroundChi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv594 · Cited by 167
Androgen regulation of micro‐RNAs in prostate cancer
Waltering, K. K., Porkka, K. P., Jalava, S. E., Urbanucci, A., Kohonen, P. J., Latonen, L. M., Kallioniemi, O. P., Jenster, G., & Visakorpi, T. (2011) · The Prostate · doi:10.1002/pros.21276 · Cited by 166 · cited 1×
“Some miRNAs are regulated via the androgen receptor (AR), while others regulate AR expression [8, 9].”
BackgroundAre androgen receptor variants a substitute for the full-length receptor?
Ji, L., der Steen, T. V., & Tindall, D. J. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.13 · Cited by 138
Hagman, Z., Haflidadóttir, B. S., Ceder, J. A., Larne, O., Bjartell, A., Lilja, H., Edsjö, A., & Ceder, Y. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.131 · Cited by 127 · cited 1×
“We also identified miR-205 to be the most downregulated miRNA in CRPC tissue, confirming previous results [14, 19].”
ResultTreatment of mCRPC in the AR-axis-targeted therapy-resistant state
Chi, K. N., Hotte, S. J., Joshua, A. M., North, S. A., Wyatt, A. W., Collins, L. L., & Saad, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv267 · Cited by 123 · cited 1×
“These investigations culminated with the development of a number of new and more potent drugs to suppress AR signaling, such as abiraterone acetate or enzalutamide [2].”
BackgroundDifferences in microRNA detection levels are technology and sequence dependent
Leshkowitz, D., Horn-Saban, S., Parmet, Y., & Feldmesser, E. (2013) · RNA · doi:10.1261/rna.036475.112 · Cited by 112 · cited 1×
“The differences in miRNA expression are not only dependent on the technology used for their detection, but also on the sequence of the transcript [18].”
BackgroundKrause, W. C., Shafi, A. A., Nakka, M., & Weigel, N. L. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.06.013 · Cited by 91
Noncoding RNAs in Prostate Cancer: The Long and the Short of It
Bolton, E. M., Tuzova, A. V., Walsh, A. L., Lynch, T. H., & Perry, A. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1989 · Cited by 79
An update on enzalutamide in the treatment of prostate cancer
Merseburger, A. S., Haas, G. P., & von Klot, C. A. (2014) · Therapeutic Advances in Urology · doi:10.1177/1756287214555336 · Cited by 67 · cited 1×
“The AR signaling pathway is a relevant target in patients with metastatic PCa [20, 21].”
BackgroundLei, L., Huang, Y., & Gong, W. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1882-5 · Cited by 60 · cited 1×
“MiR92b, a known oncogenic miRNA [15, 16], is significantly upregulated in primary PCa versus BPH tissue.”
BackgroundmiR-663 Induces Castration-Resistant Prostate Cancer Transformation and Predicts Clinical Recurrence
Li, J., Deng, Z., Xu, C., Yu, Y., Li, Y., Yang, C., Chen, J., Liu, Z., Huang, G., Li, L., et al. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24510 · Cited by 59 · cited 1×
“1 3 overexpression promotes cell proliferation and invasion [27].”
BackgroundMiR‐1247‐5p is overexpressed in castration resistant prostate cancer and targets MYCBP2
Scaravilli, M., Porkka, K. P., Brofeldt, A., Annala, M., Tammela, T. L. J., Jenster, G. W., Nykter, M., & Visakorpi, T. (2015) · The Prostate · doi:10.1002/pros.22961 · Cited by 57
Li, Q., Shen, K., Zhao, Y., Ma, C., Liu, J., & Ma, J. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-302 · Cited by 50 · cited 1×
“MiR92b, a known oncogenic miRNA [15, 16], is significantly upregulated in primary PCa versus BPH tissue.”
BackgroundLǚ, K., Liu, C., Tao, T., Zhang, X., Zhang, L., Sun, C., Wang, Y., Chen, S., Xu, B., & Chen, M. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.04.037 · Cited by 48 · cited 1×
“Furthermore, increased expression of miR-19a in CRPC tissue has been reported, and the latter miRNA regulates proliferation and apoptosis by direct targeting of the BTG1 tumor suppressor gene [11].”
BackgroundBenoist, G. E., van Oort, I. M., Boerrigter, E., Verhaegh, G. W. C. T., van Hooij, O., Groen, L., Smit, F. P., de Mol, P., Hamberg, P., Dezentjé, V. O., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa095 · Cited by 42 · cited 1×
“In a recent prospective clinical study, we have found that miR-3687 can be detected in plasma and whole blood, and that miR-3687 is a novel prognostic marker for enzalutamide treatment response in mCRPC patients [29].”
BackgroundSelf-citationUncovering the roles of miRNAs and their relationship with androgen receptor in prostate cancer
Song, C., Huan, C., ChaoYang, X., & Ru, G. (2014) · IUBMB Life · doi:10.1002/iub.1281 · Cited by 41
Sternberg, C. N., Baskin-Bey, E. S., Watson, M., Worsfold, A., Rider, A., & TOMBAL, B. F. (2013) · BMC Urology · doi:10.1186/1471-2490-13-58 · Cited by 40 · cited 1×
“The AR signaling pathway is a relevant target in patients with metastatic PCa [20, 21].”
BackgroundUnderstanding heterogeneity of treatment effect in prostate cancer
Aly, A., Mullins, C. D., & Hussain, A. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000172 · Cited by 19 · cited 1×
“Unfortunately, in most patients tumor cells become resistant to ADT and patients progress to so-called castration-resistant PCa (CRPC) and die within 2–4 years [1].”
Background
Cited by
Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021
Zhang, C., Sun, C., Zhao, Y., Wang, Q., Guo, J., Ye, B., & Yu, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911389 · Cited by 66
“obtained the combination of three miRNAs (miRNA-205, miRNA-3195 and miRNA-4417), which could be used as a potential biomarker for differentiating CRPC from primary PCa [139].”
BackgroundInfluentialThe Role of Androgen Receptor and microRNA Interactions in Androgen-Dependent Diseases
Bielska, A., Skwarska, A., Kretowski, A. J., & Niemira, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031553 · Cited by 23
“Furthermore, mice with CRPC treated with the miR-1205 synthetic analog (NB1205) showed smaller volumes of prostate tumour, which suggests that miR-1205 may have tumour suppressive properties in PCa.”
BackgroundInfluentialMao, Y., Yang, G., Li, Y., Liang, G., Xu, W., & Hu, M. (2022) · Cancers · doi:10.3390/cancers14153744 · Cited by 23
Padmyastuti, A., Sarmiento, M. G., Dib, M., Ehrhardt, J., Schoon, J., Somova, M., Burchardt, M., Roennau, C., & Pinto, P. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-38834-y · Cited by 17
Self-citationMicrophysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14
Metadata
- Authors
- Rönnau, C. G. H., Fussek, S., Smit, F. P., Aalders, T. W., van Hooij, O., Pinto, P. M. C., Burchardt, M., Schalken, J. A., & Verhaegh, G. W.
- Affiliations
- Universitätsmedizin Greifswald (DE)
- MDxHealth (Netherlands) (NL)
- Radboud University Medical Center (NL)
- Corresponding author
- Verhaegh, G. W.
- Venue
- World Journal of Urology
- Published
- 2021-05-14
- Volume
- 39
- Issue
- 10
- Pages
- 3789-3797
- ISSN
- 0724-4983 (ISSN-L)
- 1433-8726
- PMC
- PMC8519832
- OpenAlex
- W3163788247
- Cited by
- 28
- References
- 31
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 4 · 2023: 8 · 2022: 6
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- World Journal of Urology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- European Association of Urology
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- castration-resistant prostate cancer, miRNA expression profiling, miR-205, miR-92b, androgen deprivation therapy, tumor invasion, cell migration, cell proliferation, KLK3, miR-21, miR-141
- MeSH terms
- PC-3 Cells, Aged, Cell Movement, Humans, Male, Middle Aged, Neoplasm Invasiveness, Prostatic Hyperplasia, Prostatic Neoplasms, Up-Regulation, MicroRNAs, Cell Line, Tumor, Cell Proliferation, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.